Results 161 to 170 of about 3,103,465 (226)
Research on geographic information update index of RTK location big data. [PDF]
Zeng X, Zhou F, Ao M, Chen C.
europepmc +1 more source
openaire +3 more sources
TRPM8 levels determine tumor vulnerability to channel agonists
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo+18 more
wiley +1 more source
Big data research is everyone's research-Making epilepsy data science accessible to the global community: Report of the ILAE big data commission. [PDF]
Josephson CB+19 more
europepmc +1 more source
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte+10 more
wiley +1 more source
Application of big data technology in enterprise information security management. [PDF]
Li P, Zhang L.
europepmc +1 more source
Big data. Big potential. Big problems?
Stephen W West+5 more
openaire +3 more sources
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song+11 more
wiley +1 more source
Intersections of Big Data and IoT in Academic Publications: A Topic Modeling Approach. [PDF]
Căuniac DA+3 more
europepmc +1 more source
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source